Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|November 1, 2006

Applied Clinical Trials

  • Applied Clinical Trials-11-01-2006
  • Volume 0
  • Issue 0

eShowcase: iPlan Flow

Software disentangles delivery efficacy from drug efficacy, improving trial results

Software disentangles delivery efficacy from drug efficacy, improving trial results

BrainLab AG (Chicago, IL) has developed a system that allows targeted drug delivery into the brain for treating tumors, a technology that the company says could improve the results of drug trials and ultimately enhance the chances of regulatory approval during trials.

iPlan Flow

iPlan Flow addresses a difficult challenge, since the tight coating of blood vessels protects the brain and prevents fluids from entering it. Delivering enough drug concentration to specific brain cells is therefore problematic due to varying fluid dynamics. The technology uses magnetic resonance imaging to develop a three-dimensional image of the patient's brain. Then, it calculates the drug's distribution patterns, enabling a surgeon to identify the proper locations to place fluid delivery catheters. Potential applications include chemotherapy, gene therapy, molecular-targeted therapy, immunotherapy, and radio-immunotherapy.

BrainLab AG, (800) 784-7700, www.brainlab.com

Articles in this issue

almost 20 years ago

Building Your Clinical IT Team

almost 20 years ago

Experts Urge Major Overhaul at FDA

almost 20 years ago

Recruitment & Consent in India

almost 20 years ago

Meet the EAB: Somesh Nigam

almost 20 years ago

Merging eHR & EDC Conference

almost 20 years ago

eShowcase: Clintrace 4.1

almost 20 years ago

eShowcase: PharmaReady V3.0

Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.